Monkeypox Treatment Market Size- By Treatment, By Product Type, By Dosage Form, By Route of Administration, By Age, By Gender, By Prescription Type, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2032
Global Monkeypox Treatment Market Overview
According to SPER Market Research, the Global Monkeypox Treatment Market is estimated to reach USD 0.23 billion by 2032 with a CAGR of 10.37%. The monkeypox virus is the source of this uncommon but severe illness. Since monkey pox is a contagious disease, it can be spread by sick people, animals, or even contaminated objects. The monkeypox virus results in skin lesions and rashes on every part of the diseased body. Monkeypox symptoms and signs include fever, swollen lymph nodes, aches and chills, and muscle pain.
Impact of COVID-19 on the Global Monkeypox Treatment MarketThe recent COVID 19 pandemic has resulted in weakened immunity in those affected, which raises the risk of monkeypox virus infection. Monkeypox market expansion was boosted by a large population that was infected with COVID 19. Businesses across all industries are struggling financially as a result of the global lockdown caused by the corona virus (COVID 19) epidemic.
Scope of the Report:Report Metric Details
Market size available for years 2019-2032
Base year considered 2021
Forecast period 2022-2032
Segments covered By Treatment, By Product Type, By Dosage Form, By Route of Administration, By Age, By Gender, By Prescription Type, By End User
Regions covered Asia Pacific, Europe, Middle East and Africa, North America, Latin America
Companies Covered Bavarian Nordic, Chimerix, CIDIC Co., Ltd., EMERGENT, Hetero, Olon S.p.A, Piramal Pharma Solutions, SIGA Technologies, Teva Pharmaceutical Industries Ltd.
Global Monkeypox Treatment Market Segmentation:
By Treatment: Based on the Treatment, Global Monkeypox Treatment Market is segmented as; Medications (Analgesics, Antipruritic or Anti-itch drugs, Antipyretics, Antivirals), Vaccine (Smallpox Vaccine, JYNNEOS/Imvanex), Vaccinia Immune Globulin (VIG).
By Region: Over the forecast period, the monkeypox market in Asia Pacific is anticipated to develop at the quickest rate. Other factors contributing to the market expansion in the region include an increase in the number of patients with monkeypox, government activities to raise public awareness, and an increase in demand for the treatment.